3 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Haider Mahdi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer Carboplatin AUC 5 and paclitaxel, HCW9218 - Ovarian Cancer | Phase 2 | Withdrawn | Haider Mahdi | 2024-05-10 | 2025-01-01 | |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors ZEN003694, Niraparib - Ovarian Cancer, Recurrent Solid Tumors | Phase 1 | Withdrawn | Haider Mahdi | 2024-01-23 | 2024-10-15 | |
| Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System pembrolizumab, Sitravatinib - Recurrent Endometrial Cancer, Solid Tumors | Phase 2 | Withdrawn | Haider Mahdi | 2022-09-08 | 2023-02-27 |
Ovarian Neoplasms (2) · Endometrial Neoplasms (1)
Paclitaxel (1) · niraparib (1) · pembrolizumab (1) · sitravatinib (1)
United States (1)